Glaxo flu vaccine sales pegged at $2.1B

As the swine flu gathers pace around the world, analysts forecast windfall orders for GlaxoSmithKline's H1N1 vaccine, which they expect to generate at least $2.1 billion in sales next year. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.